Tuesday, May 30, 2023


Biotechnology News Magazine

Pharmaxis Announces 1st Patient Enrolled in Clinical Trial Studying a Potential New Treatment for Bone Marrow Cancer Myelogibrosis

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

February 22, 2021

Pharmaxis advises the phase 1c/2a trial cleared by the FDA under the Investigational New Drug (IND) scheme aims to demonstrate that PXS-5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs

Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled. The dose-escalation phase of the study that aims to select the optimum dose of PXS-5505.  This first phase, which will recruit up to 18 patients, is expected to conclude and report in 2H 2021 and will be followed by a six-month dose-expansion phase (24 patients) to evaluate safety and efficacy. Sites in other countries including the USA will be added for the dose-expansion phase.

PXS-5505 is an orally taken drug that inhibits the lysyl oxidase family of enzymes.  In pre-clinical models of myelofibrosis, PXS-5505 reversed the bone marrow fibrosis that drives morbidity and mortality in myelofibrosis and reduced many of the abnormalities associated with this disease.

Pharmaxis CEO Gary Phillips said, “PXS-5505 has demonstrated good tolerability and highly effective inhibition of the enzyme in phase 1 studies. Its potential to modify the course of the disease by directly targeting bone marrow fibrosis will make PXS-5505 an ideal monotherapy or adjunct to approved therapies in this indication. There remains a high level of unmet need in myelofibrosis and many other drugs in development have challenging side effect profiles.”

While Pharmaxis’s primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancer where it aims to breakdown the fibrotic tissue in the tumor and enhance the effect of chemotherapy treatment. Learn more here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine